CTSA Archives

Potential mechanism for myeloma drug’s variable toxicity

Apr. 30, 2014—A genetic variant is associated with toxicity of the chemotherapy drug melphalan, and could guide individualized dosing for the medication.

E-records shed light on drug response

Mar. 31, 2014—Electronic medical records linked to DNA biobanks are a valid resource for defining and understanding the genetic factors that contribute to drug response.

Mapping brain circuitry

Mar. 28, 2014—Vanderbilt investigators have used two types of neuroimaging to establish a “map” of connections for a brain region important in anxiety and addiction.

Flu boosts pneumococcal colonization

Mar. 27, 2014—Influenza and parainfluenza infections – but not other respiratory viruses – increase the risk of acquiring pneumococcal bacteria, the most common cause of severe pneumonia.

A pain in the … genes

Jan. 10, 2014—Vanderbilt researchers have discovered that variation in the gene encoding the potassium channel GIRK1 plays a role in modulating human pain perception.

Rhythm response tied to gene variant

Jun. 21, 2013—A genetic variant that increases risk for atrial fibrillation also impacts the response to a common therapy for the heart rhythm disorder.

Symposium highlights VU’s clinical, translational research

Nov. 29, 2012—Nearly $5 million in internal pilot grants to jumpstart research projects. A tripling in the number of clinical and translational research publications. Novel research tools that have been snapped up by scientists around the world.

Clinical and translational research at Vanderbilt will be funded over the next five years, thanks to a $46 million renewal grant from the National Center for Advancing Translational Sciences. (Mary Donaldson/Vanderbilt)

Vanderbilt’s CTSA lands $46 million renewal

Jul. 12, 2012—Vanderbilt University’s largest single government research grant, its Clinical and Translational Science Award (CTSA), has been renewed for another five years for $46 million.